Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/100294
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Flightless I is a key regulator of the fibroproliferative process in hypertrophic scarring and a target for a novel antiscarring therapy |
Author: | Cameron, A. Turner, C. Adams, D. Jackson, J. Melville, E. Arkell, R. Anderson, P. Cowin, A. |
Citation: | British Journal of Dermatology, 2016; 174(4):786-794 |
Publisher: | Willey-Blackwell |
Issue Date: | 2016 |
ISSN: | 0007-0963 1365-2133 |
Statement of Responsibility: | A.M. Cameron, C.T. Turner, D.H. Adams, J.E. Jackson, E. Melville, R.M. Arkell, P.J. Anderson and A.J. Cowin |
Abstract: | Background: Hypertrophic scarring carries a large burden of disease, including disfigurement, pain and disability. There is currently no effective medical treatment to reduce or prevent hypertrophic scarring. Flightless I (Flii), a member of the gelsolin family of actin remodelling proteins, is an important negative regulator of wound repair. Objectives: The objective of this study was to investigate the role of Flii as a potential regulator of hypertrophic scarring. Methods: Using human skin samples and an animal model of bleomycin-induced hypertrophic scarring in mice that overexpress or have reduced expression of Flii, we investigated its effect on dermal fibrosis and hypertrophic scarring. Results: Flii expression was increased in human burns and hypertrophic scars. A similar increase in Flii was observed in hypertrophic scars formed in mice post-treatment with bleomycin. However, Flii-deficient (Flii+/−) mice had reduced scarring in response to bleomycin evidenced by decreased dermal thickness, smaller cross-sectional scar areas, fewer myofibroblasts and a decreased collagen I/III ratio. In contrast, bleomycin-treated Flii-overexpressing mice (FliiTg/Tg) showed increased scar dermal thickness, larger cross-sectional scar areas, more myofibroblasts and an increased collagen I/III ratio. Injecting developing scars with a Flii neutralizing antibody led to a significant reduction in the size of the scars and a reduction in the collagen I/III ratio. Conclusion: This study identifies Flii as a profibrotic agent that contributes to excessive scar formation. Reducing its activity using neutralizing antibodies is a promising approach for reducing hypertrophic scarring. |
Keywords: | Animals Mice, Inbred BALB C Humans Cicatrix, Hypertrophic Burns Disease Models, Animal Collagen Microfilament Proteins Bleomycin Carrier Proteins Cytoskeletal Proteins Receptors, Cytoplasmic and Nuclear Antibiotics, Antineoplastic Female Transforming Growth Factor beta1 Antibodies, Neutralizing Myofibroblasts |
Rights: | © 2015 British Association of Dermatologists |
DOI: | 10.1111/bjd.14263 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1038104 http://purl.org/au-research/grants/nhmrc/1002009 |
Published version: | http://dx.doi.org/10.1111/bjd.14263 |
Appears in Collections: | Aurora harvest 7 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.